Apr 272011
 

Those patients with severe acute lung injury due to pneumonia or aspiration who received the rSP-C surfactant product did no better on important outcomes (28-day survival, need for ventilation, organ-failure-free days) than those receiving usual care, report Spragg et al.(n=843). AJRCCM 2011;183:1055-1061.

Get our weekly email update, and explore our library of practice updates and review articles.

PulmCCM is an independent publication not affiliated with or endorsed by any organization, society or journal referenced on the website. (Terms of Use | Privacy Policy)

0 Comments

Acute lung injury not improved by recombinant surfactant protein C product